Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
dc.contributor.author | Jaoko Walter G. | |
dc.contributor.author | Nakwagala, Frederick N. | |
dc.contributor.author | Anzala, Omu | |
dc.contributor.author | Manyonyi, Gloria Omosa | |
dc.contributor.author | Birungi, Josephine | |
dc.contributor.author | Nanvubya, Annet | |
dc.contributor.author | Bashir, Farah | |
dc.contributor.author | Bhatta, Kirana | |
dc.contributor.author | Ogutu, Hilda | |
dc.contributor.author | Wakasiaka, Sabina | |
dc.contributor.author | Matu, Lucy | |
dc.contributor.author | Waruingi, Wambui | |
dc.contributor.author | Odada, Jane | |
dc.contributor.author | Oyaro, Micah | |
dc.contributor.author | Indangasi, Jackton | |
dc.contributor.author | Ndinya-Achola, JO | |
dc.contributor.author | Konde, Carol | |
dc.contributor.author | Mugisha, Emmanuel | |
dc.contributor.author | Fast, Patricia | |
dc.contributor.author | Schmidt, Claudia | |
dc.contributor.author | Gilmour, Jill | |
dc.contributor.author | Tarragona, Tony | |
dc.contributor.author | Smith, Carol | |
dc.contributor.author | Barin, Burc | |
dc.contributor.author | Dally, Len | |
dc.contributor.author | Johnson, Bruce | |
dc.contributor.author | Muluubya, Andrew | |
dc.contributor.author | Nielsen, Leslie | |
dc.contributor.author | Hayes, Peter | |
dc.contributor.author | Boaz, Mark | |
dc.contributor.author | Hughes, Peter | |
dc.contributor.author | Hanke, Tom´aˇs | |
dc.contributor.author | McMichael, Andrew | |
dc.contributor.author | Bwayo, JJ | |
dc.contributor.author | Kaleebu, Pontiano | |
dc.date.accessioned | 2013-02-18T06:48:46Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | Science direct | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/18440674 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10065 | |
dc.description.abstract | Summary: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN- ) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa. | en |
dc.language.iso | en | en |
dc.subject | HIV—AIDS vaccine; | en |
dc.title | Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa | en |
dc.type | Article | en |
Files in this item
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]